Research graph
References from Gemcitabine and carboplatin in carcinoma of unknown primary site (CUP) in elderly patients: Analysis of a phase 2 Adelaide Cancer Trials and Education Collaborative (ACTEC) study. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer of unknown primary site
2008 · External reference
Metastases of undetermined source
10.1016/s0147-0272(79)80019-7 · 1979 · External reference
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study
10.1200/jco.2000.18.17.3101 · 2000 · External reference
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study
10.1200/jco.20.6.1651 · 2002 · External reference
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
10.1080/02841860510029554 · 2005 · External reference
Epidemiology of unknown primary tumours: incidence and population based survival of 1285 patients in southeast Netherlands, 1984–1992
10.1016/s0959-8049(01)00378-1 · 2002 · External reference
Unresolved reference
External reference
Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden
10.1002/cncr.10593 · 2002 · External reference
Unresolved reference
2000 · External reference
Diagnostic and therapeutic management of cancer of an unknown primary
10.1016/s0959-8049(03)00547-1 · 2003 · External reference
Probing the unknown in cancer of unknown primary: which way is the right way?
10.1093/annonc/mdp609 · 2010 · External reference
Low serum albumin levels and liver metastases are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
10.1002/cncr.22300 · 2006 · External reference
New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis
10.1016/j.clon.2008.09.007 · 2009 · External reference
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study
10.1038/sj.bjc.6603440 · 2006 · External reference
Carcinoma of unknown primary site: treatment with 1-h paclitaxel, carboplatin, and extended-schedule etoposide
10.1200/jco.1997.15.6.2385 · 1997 · External reference
Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin
10.1023/a:1008369812295 · 2000 · External reference
Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial
10.1097/ppo.0b013e3181c6aa89 · 2010 · External reference
Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis
10.1016/j.ctrv.2009.05.005 · 2009 · External reference
Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan
10.1007/s10147-006-0599-9 · 2006 · External reference
Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
10.1038/sj.bjc.6604829 · 2009 · External reference
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network
10.1200/jco.2006.09.3047 · 2007 · External reference
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
10.1200/jco.2003.12.104 · 2003 · External reference
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study
10.1002/cncr.22379 · 2006 · External reference
A randomized trial of cisplatin with or without gemcitabine in patients with carcinoma of an unknown primary and without poor prognostic factors: results of the GEFCAPI02 trial
2008 · External reference
Can baseline complete geriatric assessment (CGA) predict toxicity in elderly non-small cell lung cancer (NSCLC) patients (pts) receiving combination chemotherapy? Results from the first 100 pts in the prospective multicenter NVALT-3 study
2007 · External reference
Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population based study
10.1002/(sici)1097-0142(19980601)82:11<2123::aid-cncr6>3.0.co;2-w · 1998 · External reference
10.1200/jco.2005.02.527
10.1200/jco.2005.02.527 · 2005 · External reference
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site
10.1200/jco.2002.04.019 · 2002 · External reference
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature
10.1200/jco.2007.10.6583 · 2007 · External reference
Polypharmacy in the elderly. Early intervention can prevent complications
1997 · External reference
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer
10.2165/00002512-200219010-00003 · 2002 · External reference
Are the elderly underrepresented in clinical drug trials?
10.1177/009127009903901101 · 1999 · External reference
